New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MLNX;ISIS;INVN;TPX;CRUS From The Last 14 Days
Check below for free stories on MLNX;ISIS;INVN;TPX;CRUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
11:30 EDTCRUSCirrus Logic completes acquisition of Wolfson Microelectronics
Cirrus Logic announced that it has completed its acquisition of Wolfson Microelectronics. Cirrus Logic believes that the acquisition will strengthen its position as a market leader with a highly differentiated global customer base and end-to-end signal processing solutions, including integrated circuits and software for portable audio applications. Cirrus Logic will provide financial information for the combined company when it reports 2Q15 results.
August 18, 2014
10:29 EDTINVNGoldman cuts sector view on semiconductors to Cautious
Subscribe for More Information
10:01 EDTINVNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:03 EDTINVNOn The Fly: Pre-market Movers
Subscribe for More Information
08:04 EDTINVNSemiconductors sector downgraded to Cautious from Neutral at Goldman
Goldman downgraded the Semiconductors sector to Cautious given signs the cycle is turning based on expectations for a slowdown in semiconductor revenue growth, above trend semi unit shipments that should normalize, and stretching lead times. As a result, the analyst sees risk to Q4 estimates and sees further downside of 10%-25% for the SOX (SOX) and downgraded NXP Semiconductors (NXPI) to Sell from Neutral, InvenSense (INVN) to Neutral from Buy, and removed Maxim Integrated (MXIM) from the Conviction Buy List.
05:23 EDTINVNInvenSense downgraded to Neutral from Buy at Goldman
Goldman Sachs downgraded InvenSense (INVN) to Neutral citing valuation with shares near its $25 price target. Goldman also believes the near-term catalyst of share gains at Apple (AAPL) has passed. InvenSense closed Friday down 1c to $24.99.
August 15, 2014
07:01 EDTISISIsis Pharmaceuticals earns $2M from advancement of ISIS-SMN from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2M milestone payment from Biogen (BIIB) related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy.
August 12, 2014
10:07 EDTCRUSCirrus Logic losing China OEM market share to Qualcomm, says Rosenblatt
Subscribe for More Information
August 8, 2014
10:00 EDTINVNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:24 EDTINVNInvenSense initiated with a Buy at Canaccord
Target $29.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use